These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38876129)

  • 1. Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study.
    Golder V; Kandane-Rathnayake R; Li N; Louthrenoo W; Chen YH; Cho J; Lateef A; Hamijoyo L; Luo SF; Wu YJ; Navarra SV; Zamora L; Li Z; Sockalingam S; Katsumata Y; Harigai M; Hao Y; Zhang Z; Basnayake D; Chan M; Kikuchi J; Takeuchi T; Bae SC; Goldblatt F; Oon S; O'Neill S; Ng K; Law A; Tugnet N; Kumar S; Tee C; Tee M; Ohkubo N; Tanaka Y; Lau CS; Hoi A; Nikpour M; Morand EF;
    Lancet Rheumatol; 2024 Jun; ():. PubMed ID: 38876129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study.
    Golder V; Kandane-Rathnayake R; Huq M; Nim HT; Louthrenoo W; Luo SF; Wu YJ; Lateef A; Sockalingam S; Navarra SV; Zamora L; Hamijoyo L; Katsumata Y; Harigai M; Chan M; O'Neill S; Goldblatt F; Lau CS; Li ZG; Hoi A; Nikpour M; Morand EF;
    Lancet Rheumatol; 2019 Oct; 1(2):e95-e102. PubMed ID: 38229349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study.
    Golder V; Kandane-Rathnayake R; Huq M; Louthrenoo W; Luo SF; Wu YJ; Lateef A; Sockalingam S; Navarra SV; Zamora L; Hamijoyo L; Katsumata Y; Harigai M; Chan M; O'Neill S; Goldblatt F; Lau CS; Li ZG; Hoi A; Nikpour M; Morand EF;
    Lancet Rheumatol; 2019 Oct; 1(2):e103-e110. PubMed ID: 38229337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study.
    Kandane-Rathnayake R; Golder V; Louthrenoo W; Chen YH; Cho J; Lateef A; Hamijoyo L; Luo SF; Wu YJ; Navarra SV; Zamora L; Li Z; Sockalingam S; Katsumata Y; Harigai M; Hao Y; Zhang Z; Basnayake BMDB; Chan M; Kikuchi J; Takeuchi T; Bae SC; Oon S; O'Neill S; Goldblatt F; Ng KPL; Law A; Tugnet N; Kumar S; Tee C; Tee M; Ohkubo N; Tanaka Y; Yu D; Karyekar CS; Sing Lau C; Monk JA; Nikpour M; Hoi A; Morand EF;
    Lancet Rheumatol; 2022 Dec; 4(12):e822-e830. PubMed ID: 38261390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study.
    Cho J; Shen L; Huq M; Kandane-Rathnayake R; Golder V; Louthrenoo W; Chen YH; Hamijoyo L; Luo SF; Wu YJ; Zamora L; Li Z; Sockalingam S; Katsumata Y; Harigai M; Hao Y; Zhang Z; Basnayake D; Chan M; Kikuchi J; Takeuchi T; Bae SC; Oon S; O'Neill S; Goldblatt F; Ng KPL; Law A; Tugnet N; Kumar S; Tee C; Tee M; Ohkubo N; Tanaka Y; Navarra SV; Lau CS; Hoi A; Morand EF; Nikpour M; Lateef A;
    Lancet Rheumatol; 2023 Oct; 5(10):e584-e593. PubMed ID: 38251484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LLDAS (lupus low disease activity state) and/or remission are associated with less damage accrual in patients with systemic lupus erythematosus from a primarily Mestizo population: data from the Almenara Lupus Cohort.
    Ugarte-Gil MF; Gamboa-Cardenas RV; Reátegui-Sokolova C; Pimentel-Quiroz VR; Medina M; Elera-Fitzcarrald C; Zevallos F; Pastor-Asurza CA; Lofland J; Zazzetti F; Karyekar CS; Alarcón GS; Perich-Campos RA
    Lupus Sci Med; 2022 Feb; 9(1):. PubMed ID: 35193948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants and protective associations of the lupus low disease activity state in a prospective Chinese cohort.
    Hao Y; Oon S; Ji L; Gao D; Fan Y; Geng Y; Zhang X; Li G; Morand EF; Nikpour M; Zhang Z
    Clin Rheumatol; 2022 Feb; 41(2):357-366. PubMed ID: 34595670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission.
    Zen M; Iaccarino L; Gatto M; Saccon F; Larosa M; Ghirardello A; Punzi L; Doria A
    Ann Rheum Dis; 2018 Jan; 77(1):104-110. PubMed ID: 28970217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort study.
    Connelly K; Kandane-Rathnayake R; Hoi A; Louthrenoo W; Hamijoyo L; Cho J; Lateef A; Fen Luo S; Wu YJ; Li Z; Navarra S; Zamora L; Sockalingam S; Hao Y; Zhang Z; Katsumata Y; Harigai M; Oon S; Chan M; Chen YH; Bae SC; O'Neill S; Goldblatt F; Kikuchi J; Takeuchi T; Ling Ng KP; Tugnet N; Basnayake BMDB; Ohkubo N; Tanaka Y; Sing Lau C; Nikpour M; Golder V; Morand EF;
    Lancet Rheumatol; 2022 Dec; 4(12):e831-e841. PubMed ID: 38261391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression.
    Pitsigavdaki S; Nikoloudaki M; Garantziotis P; Silvagni E; Repa A; Marangoni A; Flouri I; Avgoustidis N; Parperis K; Fanouriakis A; Govoni M; Sidiropoulos P; Boumpas DT; Bortoluzzi A; Bertsias G
    Ann Rheum Dis; 2024 Mar; 83(4):464-474. PubMed ID: 38233103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Attainment and Protective Effects of Lupus Low Disease Activity State In Patients With Newly Diagnosed Versus Established Systemic Lupus Erythematosus.
    Golder V; Kandane-Rathnayake R; Louthrenoo W; Chen YH; Cho J; Lateef A; Hamijoyo L; Luo SF; Wu YJ; Navarra SV; Zamora L; Li Z; Sockalingam S; Katsumata Y; Harigai M; Hao Y; Zhang Z; Basnayake BMDB; Chan M; Kikuchi J; Takeuchi T; Bae SC; Oon S; O'Neill S; Goldblatt F; Ng KPL; Law A; Tugnet N; Kumar S; Tee C; Tee M; Ohkubo N; Tanaka Y; Lau CS; Nikpour M; Hoi A; Morand EF;
    J Rheumatol; 2024 May; ():. PubMed ID: 38490668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus.
    Tsang-A-Sjoe MW; Bultink IE; Heslinga M; Voskuyl AE
    Rheumatology (Oxford); 2017 Jan; 56(1):121-128. PubMed ID: 27803306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Clinical Outcome in Systemic Lupus Erythematosus Patients Followed for More Than 20 Years: The Milan Systemic Lupus Erythematosus Consortium (SMiLE) Cohort.
    Gerosa M; Beretta L; Ramirez GA; Bozzolo E; Cornalba M; Bellocchi C; Argolini LM; Moroni L; Farina N; Segatto G; Dagna L; Caporali R
    J Clin Med; 2022 Jun; 11(13):. PubMed ID: 35806873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Target in Newly Diagnosed Systemic Lupus Erythematosus: The Association of Lupus Low Disease Activity State and Remission With Lower Accrual of Early Damage.
    Floris A; Piga M; Perra D; Chessa E; Congia M; Mathieu A; Cauli A
    Arthritis Care Res (Hoboken); 2020 Dec; 72(12):1794-1799. PubMed ID: 31600023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting DORIS Remission and LLDAS in SLE: A Review.
    Parra Sánchez AR; van Vollenhoven RF; Morand EF; Bruce IN; Kandane-Rathnayake R; Weiss G; Tummala R; Al-Mossawi H; Sorrentino A
    Rheumatol Ther; 2023 Dec; 10(6):1459-1477. PubMed ID: 37798595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flare rates and factors determining flare occurrence in patients with systemic lupus erythematosus who achieved low disease activity or remission: results from a prospective cohort study.
    Hao Y; Ji L; Gao D; Fan Y; Geng Y; Zhang X; Li G; Zhang Z
    Lupus Sci Med; 2022 Mar; 9(1):. PubMed ID: 35241499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus.
    Piga M; Floris A; Cappellazzo G; Chessa E; Congia M; Mathieu A; Cauli A
    Arthritis Res Ther; 2017 Nov; 19(1):247. PubMed ID: 29126432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study.
    Apostolopoulos D; Kandane-Rathnayake R; Louthrenoo W; Luo SF; Wu YJ; Lateef A; Golder V; Sockalingam S; Navarra S; Zamora L; Hamijoyo L; Katsumata Y; Harigai M; Chan M; O'Neill S; Goldblatt F; Lau CS; Li ZG; Hoi A; Nikpour M; Morand E;
    Lancet Rheumatol; 2020 Jan; 2(1):e24-e30. PubMed ID: 38258272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lupus low disease activity state within 12 months is associated with favourable outcomes in severely active systemic lupus erythematosus.
    Kikuchi J; Hanaoka H; Saito S; Oshige T; Hiramoto K; Kaneko Y; Takeuchi T
    Rheumatology (Oxford); 2022 Aug; 61(9):3777-3791. PubMed ID: 35015824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remission and low disease activity in systemic lupus erythematosus: an achievable goal even with fewer steroids? Real-life data from a monocentric cohort.
    Tani C; Vagelli R; Stagnaro C; Carli L; Mosca M
    Lupus Sci Med; 2018; 5(1):e000234. PubMed ID: 29531772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.